AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.